GS-9822

• Description:

  GS-9822 is a potent antivira agent with nanomolar activity against wild-type HIV-1 viruses. GS-9822 potently inhibits the LEDGF/p75-integrase interaction with an IC50 of 0.07 μM. GS-9822 has high in vitro metabolic stability and favorable oral pharmacokinetic profiles with low systemic clearance in rats, dogs, and monkeys[1].

• UNSPSC:

  12352005

• Target:

  HIV

• Type:

  Reference compound

• Related Pathways:

  Anti-infection

• Applications:

  COVID-19-anti-virus

• Field of Research:

  Infection

• Assay Protocol:

  https://www.medchemexpress.com/gs-9822.html

• Solubility:

  10 mM in DMSO

• Smiles:

  CC (C) (C) O[C@@H] (C1=C (C) C=C (N=C (C2=CC=C3C (C (C4CCN (C5COC5) CC4) =NN3C) =C2) S6) C6=C1C7=CC=C (Cl) C=C7) C (O) =O

• Molecular Formula:

  C36H39ClN4O4S

• Molecular Weight:

  659.24

• References & Citations:

  [1]Bruggemans A, et al. GS-9822, a preclinical LEDGIN candidate, displays a block-and-lock phenotype in cell culture. Antimicrob Agents Chemother. 2023 May 1;65 (5) :e02328-20.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  2219362-41-9